Why this vertical is treated as a restricted category
If you run GLP-1 or weight-loss telehealth ads on Meta, you are advertising in a restricted category. Meta classifies prescription-drug advertising within its Drugs and Pharmaceuticals framework. Authorization and eligibility can become gating factors before individual creative and landing-page compliance are considered.
<div class="aac-vcallout"><em>Meta files GLP-1 and weight-loss telehealth under Drugs and Pharmaceuticals, one of its restricted categories. Authorization and eligibility can be prerequisites before creative-level compliance is even considered. Confirming Meta's current requirements early matters more than optimizing individual ads.</em></div><p style="color:#334055;font-size:15px;line-height:1.7;margin:0 0 12px">What this means in practice:</p><ul class="aac-vlist"><li><strong>Compliant ads can still be rejected.</strong> Ads that appear to follow the rules can still receive enforcement in restricted categories. Ongoing review matters.</li><li><strong>Repeat issues can affect account eligibility.</strong> Ongoing rejection patterns on a single ad account can carry consequences for that account's ability to run ads. Advertisers should review account-level notices promptly.</li><li><strong>Connected business assets matter.</strong> Enforcement can extend beyond a single ad or account, so advertisers should consider the broader business environment when reviewing risk.</li><li><strong>Compounded and FDA-approved GLP-1 products can be treated differently.</strong> For compounded products, clear regulatory disclosures and provider context are important compliance considerations.</li></ul><p style="color:#334055;font-size:15px;line-height:1.7;margin:20px 0 0">The compliance work in this category is category-level as much as ad-level. Individual creative fixes are one part; authorization, product context, and connected business assets are the others.</p><h3 class="aac-vsub-h">The authorization gate</h3><p style="color:#334055;font-size:15px;line-height:1.7;margin:0 0 12px">In this category, repeated rejection can occur when an account does not meet the authorization or eligibility requirements for prescription-drug advertising, even when individual creative choices appear compliant. Meta's Prescription Drugs policy describes authorization requirements (Business Help Center: “About Meta's Prescription Drugs advertising policy”).</p><p style="color:#334055;font-size:15px;line-height:1.7;margin:0 0 12px">For telehealth advertisers, authorization typically involves third-party certification (LegitScript is a commonly referenced provider) followed by application through Meta's Authorizations and verifications tab. Requirements and eligible entity types vary; advertisers should confirm the current process directly with Meta and the relevant certification provider.</p><p style="color:#334055;font-size:15px;line-height:1.7;margin:0 0 12px"><strong>Country availability.</strong> Prescription-drug advertising may be limited by market, advertiser type, product, and current Meta requirements. Confirm supported markets directly with Meta before launch.</p><p style="color:#334055;font-size:15px;line-height:1.7;margin:0"><strong>Compounded products.</strong> Compounded semaglutide and similar products may involve different eligibility, authorization, and disclosure considerations from FDA-approved brand drugs. Confirm the applicable requirements before launching campaigns.</p>
Common enforcement patterns advertisers see in this vertical
Below are patterns that GLP-1 telehealth advertisers commonly encounter. They range from single-ad rejections to broader account-level effects. Understanding the broader context can be useful when assessing an individual enforcement event.
<div class="aac-vcallout"><em>GLP-1 telehealth advertisers commonly see a few patterns of enforcement, ranging from single-ad rejections to broader account-level effects. The patterns below describe what advertisers can encounter; they do not describe how to diagnose or respond in detail. That is where product and specialist guidance come in.</em></div><div class="aac-scen-grid"><div class="aac-scen-card aac-scen-card--sev-1"><div class="aac-scen-card__head"><span class="aac-scen-card__num">Pattern 01 · Creative and claims</span><div class="aac-scen-card__icon"><svg viewBox="0 0 40 40" fill="none" stroke="currentColor" stroke-width="1.75" stroke-linecap="round" stroke-linejoin="round"><rect x="6" y="10" width="28" height="20" rx="2"/><rect x="10" y="14" width="8" height="8" rx="1"/><line x1="21" y1="16" x2="30" y2="16" opacity="0.6"/><line x1="5" y1="31" x2="35" y2="9" stroke-width="2.5"/></svg></div></div><h4 class="aac-scen-card__title">Individual ad flagged for health-related claims</h4><p class="aac-scen-card__body">Individual ad rejections can involve efficacy claims, before-and-after framing, quantified outcomes, or language that directly addresses the viewer's health condition.</p></div><div class="aac-scen-card aac-scen-card--sev-2"><div class="aac-scen-card__head"><span class="aac-scen-card__num">Pattern 02 · Product / authority mismatch</span><div class="aac-scen-card__icon"><svg viewBox="0 0 40 40" fill="none" stroke="currentColor" stroke-width="1.75" stroke-linecap="round" stroke-linejoin="round"><rect x="7" y="16" width="26" height="8" rx="4"/><line x1="20" y1="16" x2="20" y2="24"/><path d="M28 8 L32 4 L36 8 L32 12 Z" fill="currentColor" opacity="0.7"/></svg></div></div><h4 class="aac-scen-card__title">Brand-drug references outside the advertiser's authorization</h4><p class="aac-scen-card__body">Ads or landing pages that reference FDA-approved brand drugs (such as Wegovy, Ozempic, Mounjaro, or Zepbound) can create compliance considerations when the advertiser holds authorization for a different product. The ad, landing page, and advertiser authorization should describe consistent products.</p></div><div class="aac-scen-card aac-scen-card--sev-3"><div class="aac-scen-card__head"><span class="aac-scen-card__num">Pattern 03 · Account-level restriction</span><div class="aac-scen-card__icon"><svg viewBox="0 0 40 40" fill="none" stroke="currentColor" stroke-width="1.75" stroke-linecap="round" stroke-linejoin="round"><rect x="6" y="10" width="6" height="22" rx="1" fill="currentColor" opacity="0.85"/><rect x="15" y="16" width="6" height="16" rx="1" fill="currentColor" opacity="0.6"/><rect x="24" y="22" width="6" height="10" rx="1" fill="currentColor" opacity="0.4"/><path d="M8 12 L34 28" stroke-dasharray="2 2"/></svg></div></div><h4 class="aac-scen-card__title">Account-level effects, including changes in spending capacity</h4><p class="aac-scen-card__body">Some enforcement actions occur at the account level, including changes in spending capacity or other restrictions. These actions may relate to the account's broader history rather than a single ad.</p></div><div class="aac-scen-card aac-scen-card--sev-4"><div class="aac-scen-card__head"><span class="aac-scen-card__num">Pattern 04 · Multi-account impact</span><div class="aac-scen-card__icon"><svg viewBox="0 0 40 40" fill="none" stroke="currentColor" stroke-width="1.75" stroke-linecap="round" stroke-linejoin="round"><rect x="4" y="4" width="12" height="12" rx="1" fill="currentColor" opacity="0.85"/><rect x="24" y="4" width="12" height="12" rx="1" opacity="0.7"/><rect x="4" y="24" width="12" height="12" rx="1" opacity="0.55"/><rect x="24" y="24" width="12" height="12" rx="1" opacity="0.4"/></svg></div></div><h4 class="aac-scen-card__title">Effects extending beyond a single ad account</h4><p class="aac-scen-card__body">ComplyAi uses <strong>Asset Risk Propagation</strong> to describe how enforcement exposure may extend beyond an individual ad to other connected business assets. The potential impact varies by business structure and the relationships between those assets.</p></div></div>
Positioning considerations for GLP-1 advertising
Below are positioning considerations for GLP-1 telehealth ads. These are directional, not approval guarantees. Landing-page compliance and authorization requirements still apply, and every ad should be evaluated in the context of the specific product and advertiser.
<ul class="aac-vlist"><li><strong>Describe the product accurately.</strong> Language should match the product the advertiser is authorized to promote, whether that is telehealth consultation, an FDA-approved brand medication, or a compounded product.</li><li><strong>Prefer clinical and process framing over outcome promises.</strong> Language about the treatment process, provider involvement, and consultation is generally more appropriate than language centered on quantified weight-loss outcomes.</li><li><strong>Make provider and authorization context clear.</strong> Board-certified physician involvement, licensed clinician review, and other credentials, where accurate, provide relevant context.</li><li><strong>Keep the ad and landing page consistent.</strong> Meta evaluates the destination alongside the ad. Copy that clears the ad but not the landing page can still be rejected.</li></ul><p style="color:#334055;font-size:15px;line-height:1.7;margin:20px 0 0">These are directional considerations, not a whitelist. In a restricted category, compliant positioning can still receive enforcement, so treat these as inputs to a broader compliance review, not as guarantees.</p>
Patterns that increase enforcement risk
These patterns can increase review or enforcement risk. Advertisers should evaluate them in the context of the full ad, landing page, product, and authorization requirements before submission.
<ul class="aac-vlist"><li>Direct weight-loss outcome claims that quantify a result over a defined time.</li><li>Before-and-after imagery or visible body-shape transformation content.</li><li>Second-person language that directly addresses the viewer's health condition.</li><li>Brand-drug references without matching advertiser authorization.</li><li>Quantified efficacy claims with specific percentages or pounds, including where the underlying claim is study-supported.</li><li>Conflation of compounded medications with brand-name approved drugs.</li><li>Drug imagery (pills, syringes, vials).</li></ul><p style="color:#334055;font-size:15px;line-height:1.7;margin:20px 0 0">These patterns can increase review or enforcement risk. Advertisers should evaluate them in the context of the full ad, landing page, product, and authorization requirements.</p>
Landing-page elements to review for compliance
The landing-page elements below can help make the product, provider, and regulatory context clearer to users and reviewers. Advertisers should review the landing page as part of the broader advertising surface, rather than treating it as separate from the creative.
<ul class="aac-vlist"><li><strong>Prescription context.</strong> The landing page should communicate clearly that a prescription and provider consultation are involved.</li><li><strong>Licensed-provider documentation.</strong> Provider credentials and state licensure information visible on the destination page.</li><li><strong>Regulatory disclosures.</strong> For compounded products, disclosures such as “not FDA-approved” and information about the prescribing arrangement.</li><li><strong>Clinical / regulatory tone.</strong> Language that a telehealth practice would use, rather than direct-response marketing language.</li><li><strong>No before-and-after imagery on the landing page.</strong> The destination is part of the review surface, not separate from it.</li><li><strong>No quantified outcome claims in headline or hero.</strong> Reserve outcome discussions for contexts where they can be properly substantiated.</li></ul>
Considerations when enforcement occurs
When enforcement occurs on a GLP-1 telehealth account, the right response depends on the decision, the affected asset, and the product and authorization context. ComplyAi helps teams understand what happened, assess the connected business surface, and determine the appropriate next step.
<p style="color:#334055;font-size:15px;line-height:1.7;margin:0 0 12px">When enforcement occurs, the right response depends on the specific decision, the assets affected, and the product and authorization context. Publicly available enforcement messages can be broad; understanding the decision and its policy context helps teams determine the appropriate response.</p><p style="color:#334055;font-size:15px;line-height:1.7;margin:0 0 12px">Considerations advertisers commonly weigh:</p><ul class="aac-vlist"><li>What decision has been communicated, and which asset it applies to.</li><li>Which product and authorization the advertiser holds relative to what appeared in the ad and landing page.</li><li>Whether the enforcement is limited to a single ad, or extends to broader account-level effects.</li><li>What connected business assets could be affected.</li></ul><p style="color:#334055;font-size:15px;line-height:1.7;margin:20px 0 0">Broader guidance on account-level enforcement situations lives at <a href="/blog/meta-ad-account-reinstatement" class="aac-vlink">Meta Ad Account Reinstatement</a>.</p>
Enforcement can extend across related lanes
Enforcement patterns can extend beyond a single account or vertical. GLP-1 telehealth is part of a broader restricted-health advertising environment, and changes in adjacent lanes can shape what GLP-1 advertisers should watch for.
<p style="color:#334055;font-size:15px;line-height:1.7;margin:0 0 12px">Enforcement patterns in restricted-health advertising can extend across related lanes rather than sitting entirely within a single vertical. GLP-1 telehealth is part of a broader restricted category that includes other regulated-health advertising.</p><ul class="aac-vlist"><li><strong>Adjacent lanes can inform GLP-1 compliance planning.</strong> Changes in policy focus or advertising conditions in adjacent restricted-health lanes can be relevant context for GLP-1 advertisers.</li><li><strong>Brand-drug and compounded-product distinctions can matter.</strong> Advertisers should evaluate product identity, authorization, and disclosure requirements separately rather than assuming that rules or outcomes for one product type automatically apply to another.</li></ul><p style="color:#334055;font-size:15px;line-height:1.7;margin:20px 0 0">Broader thinking on how to plan advertising in restricted categories lives at the Pillar 5 hub <a href="/blog/scale-meta-ads-safely" class="aac-vlink">Scale Meta Ads Safely</a>.</p>